|1.||Triebel, Frédéric: 4 articles (01/2014 - 09/2007)|
|2.||Marcu, Manon: 3 articles (01/2010 - 09/2007)|
|3.||Brignone, Chrystelle: 3 articles (01/2010 - 09/2007)|
|4.||Grygar, Caroline: 3 articles (01/2010 - 09/2007)|
|5.||Speiser, Daniel E: 2 articles (01/2014 - 01/2011)|
|6.||Romero, Pedro: 2 articles (01/2014 - 01/2011)|
|7.||Ji, Mei: 1 article (11/2015)|
|8.||Yang, Yan: 1 article (11/2015)|
|9.||Zhang, Chu: 1 article (11/2015)|
|10.||Hu, Wenwei: 1 article (11/2015)|
|1.||Renal Cell Carcinoma (Grawitz Tumor)
10/01/2009 - "A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma."
10/01/2009 - "Patients with advanced renal cell carcinoma were treated with escalating doses of IMP321 s.c. "
10/01/2009 - "Twenty-one advanced renal cell carcinoma patients received 119 injections of IMP321 at doses ranging from 0.050 to 30 mg/injection s.c. "
11/01/2015 - "IMP321 is formed of an extracellular portion of human LAG-3 fused to the Fc fraction of human IgG1 and has shown increased T cell responses and tolerability in phase I studies on advanced renal cell cancer. "
|2.||Melanoma (Melanoma, Malignant)
01/01/2014 - "We investigated in 12 patients with advanced stage IV melanoma the effect of multiple MART-1 analog peptide vaccinations with (n = 6) or without (n = 6) IMP321 (LAG-3Ig fusion protein) as an adjuvant in combination with lymphodepleting chemotherapy and adoptive transfer of autologous PBMCs at day (D) 0 (Trial registration No: NCT00324623). "
06/01/2013 - "This phase I study was conducted to determine the safety profile and maximum tolerated dose (MTD) of IMP321, a soluble lymphocyte activation gene-3 (LAG-3) Ig fusion protein and MHC Class II agonist, combined with gemcitabine in patients with advanced pancreatic adenocarcinoma. "
06/01/2013 - "A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma."
01/01/2011 - "Recent advances in the clinical development of the therapeutic reagent IMP321, hLAG-3-Ig, for cancer treatment. "
09/15/2007 - "Thus, IMP321 has many properties that confirm its potential to be a new class of immunopotentiator in cancer patients."
10/01/2009 - "injections of doses above 6 mg. IMP321 induced both sustained CD8 T-cell activation and an increase in the percentage of long-lived effector-memory CD8 T cells in all patients at doses above 6 mg. Tumor growth was reduced and progression-free survival was better in those patients receiving higher doses (>6 mg) of IMP321: 7 of 8 evaluable patients treated at the higher doses experienced stable disease at 3 months compared with only 3 of 11 in the lower dose group (P = 0.015). "
11/01/2015 - "When combined with paclitaxel, IMP321 has exerted immune enhancement and tumor inhibition with no significant IMP321-related adverse events. "
|1.||Immunoglobulin G (IgG)
|1.||Drug Therapy (Chemotherapy)